Medical Genetics – Hereditary Tumor Syndromes
Cowden Disease | Omicron Clinic Quebec
Cowden disease — also called Cowden syndrome or, in its broader conception integrating related phenotypes, PTEN hamartoma tumor syndrome (PHTS, PTEN Hamartoma Tumor Syndrome) — is a rare hereditary tumor syndrome with autosomal dominant inheritance, caused in the majority of cases by a pathogenic germline mutation of a tumor suppressor gene. PTEN (Phosphatase and TENsin homolog) located on chromosome 10q23. First described in 1963 by Lloyd and Dennis in a patient named Rachel Cowden, the disease is clinically characterized by a combination of multiple hamartomas - benign disorganized tumors composed of normal but aberrantly arranged mature tissues - affecting virtually every tissue in the body, and a very significantly elevated risk of developing several cancers, principally breast cancer (cumulative lifetime risk of 85 %), thyroid cancer (35 %), endometrial cancer (28 %) and, to a lesser extent, colorectal cancer (9 %) and kidney cancer (34 %). The estimated prevalence of Cowden's disease is around 1 case per 200,000 to 250,000 people in the general population, although this figure is probably underestimated due to the great variability in phenotypic expression and the frequency of underdiagnosis, particularly in patients whose characteristic cutaneous manifestations (tricholemmomas, acral keratotic papules) are unrecognized by clinicians. The PTEN protein is a major negative regulator of the PI3K/AKT/mTOR signalling pathway, which controls cell proliferation, survival, migration and angiogenesis; loss of PTEN function through germline mutation leads to constitutive activation of this pro-proliferative pathway, favoring hamartoma formation and progression to malignant transformation. Management of Cowden's disease is based on genetic confirmation of the diagnosis, family genetic counseling and the implementation of an intensified multi-organ surveillance program for early detection of associated cancers at a curable stage.
Genetics and Molecular Biology
Understanding the biology of PTEN is essential for grasping the diversity of clinical manifestations and the implications for genetic counseling:
- The gene PTEN codes a dual-specificity phosphatase (protein and lipid) whose lipid function is the most clinically important: it dephosphorylates phosphatidylinositol-3,4,5-triphosphate (PIP3) to PIP2, thus opposing the action of PI3 kinase (PI3K) and inhibiting the AKT/mTOR activation cascade; loss of PTEN removes this brake and maintains the cell in a state of constitutive pro-survival and pro-proliferative signaling
- Autosomal dominant transmission with high penetrance but variable expressivity: a single mutated allele inherited from an affected parent is sufficient to confer predisposition (germline heterozygosity), with a 50% % risk of transmission to each child; the severity of the disease and the affected organs vary considerably from one person to another within the same family, even for an identical mutation
- Approximately 25 to 30 % of cases result from a de novo mutation (not inherited from parents), meaning that a negative family history cannot exclude the diagnosis in a patient with suggestive clinical criteria.
- More than 300 different pathogenic mutations of PTEN have been listed in the databases: nonsense mutations, missense mutations, frameshift mutations, splicing mutations, and large deletions; mutations affecting the catalytic phosphatase domain (exons 5 to 8) are associated with a more severe clinical phenotype in some studies
- A mutation PTEN germline is identified in only 25 to 35 % of patients meeting the clinical criteria for Cowden disease according to NCCN criteria; other patients may have mutations in modifier genes.KLLN, SDHB/C/D, PIK3CA, AKT1) or PTEN promoter methylation; however, PTEN mutation testing remains the first-line genetic examination
- The PTEN Hamartoma Tumor Syndrome spectrum includes, besides Cowden disease, Bannayan-Riley-Ruvalcaba syndrome (macrocephaly, multiple lipomas, genital pigmentation, hamartomas), Proteus syndrome (progressive asymmetric overgrowth of bones and soft tissues), and Lhermitte-Duclos disease (cerebellar ganglioneuromatosis) – all linked to germline mutations in PTEN
Clinical manifestations
Cowden disease is characterized by a spectrum of hamartomatous and neoplastic manifestations affecting multiple organs, grouped according to their diagnostic value into pathognomonic, major, and minor criteria by the International Cowden Disease Consortium (NCCN):
| System | Event | Frequency and characteristics |
|---|---|---|
| Skin and mucous membranes (pathognomonic criteria) | Multiple facial trichilemmomas; acrokeratotic papules of hands and feet; mucosal papules and fibromas (gums, oral mucosa); Cowden facial skin lesion (perinasal and peri-orbital translucent papules) | Présents dans 90 à 100 % des cas confirmés ; les tricholemmomes sont des tumeurs bénignes des follicules pileux se manifestant comme de petites papules couleur chair sur le visage (joues, nez, front, lèvres) souvent méprises pour des verrues ; les papules muqueuses (cobblestoning gingival, mucosal papules) sur la langue et les gencives sont très évocatrices ; leur présence constitue un signal d'alarme dermatologique devant conduire à une évaluation génétique |
| His | Breast cancer (invasive or ductal carcinoma in situ); multiple fibroadenomas; extensive fibrocystic breast disease | Lifetime cumulative risk of breast cancer of 85% (%) (compared to 12% [%] in the general population); earlier average age at diagnosis than in the general population (early 40s); affects women and, more rarely, men (increased risk of male breast cancer); multiple fibroadenomas and diffuse dense mastopathy are common and complicate mammographic surveillance |
| Thyroid | Thyroid cancer (mainly follicular and vesicular carcinoma, rarely papillary); multinodular goiter; adenomatous thyroid | Lifetime cumulative risk of thyroid cancer of 35 %(versus 1 % in the general population); mainly follicular or vesicular differentiated carcinomas, unlike the general population where papillary carcinoma predominates; benign multinodular goiters are very common (40 to 65 % ) and often constitute the first thyroid manifestation leading to diagnosis |
| Endometrium and uterus | Endometrial cancer (endometrioid carcinoma); multiple uterine fibroids | Lifetime cumulative risk of endometrial cancer of 28 % (compared to 2.5 % in the general population); earlier age of onset than in the general population; uterine fibroids are common and often multiple |
| Colon and rectum | Colorectal hamartomatous polyps (Peutz-Jeghers-like polyps, ganglioneuromatous polyps); colorectal carcinoma | Frequent benign colorectal polyps (35 to 65 %) but a moderately increased risk of colorectal cancer (9 %) compared to the general population; sometimes extensive colorectal hamartomatous polyposis requiring regular surveillance colonoscopy |
| Rein | Clear cell renal cell carcinoma and papillary renal cell carcinoma | Lifetime cumulative risk of kidney cancer of 34 % according to recent studies, although this figure is still subject to debate; abdominal MRI surveillance is recommended by some expert groups |
| Brain and central nervous system | Lhermitte-Duclos disease (cerebellar dysplastic gangliocytoma); macrocephaly (head circumference > 97th percentile) | Lhermitte-Duclos disease is pathognomonic of PTHS in adults: a benign cerebellar hamartoma manifesting with symptoms of increased intracranial pressure, ataxia, or diplopia; macrocephaly is present in 80 % of cases and is often the first sign leading to diagnosis in children |
| Gastrointestinal tract | Hamartomatous polyps of the esophagus, stomach, and small intestine; acanthosis nigricans of the esophagus | Acanthosis glycogenica of the esophagus – a whitish, plaque-like appearance of the esophagus on endoscopy – is highly suggestive of Cowden disease in a patient with other compatible manifestations. |
ℹ️
La macrocéphalie (périmètre crânien supérieur au 97e percentile) est présente chez environ 80 % des porteurs de mutation PTEN et constitue souvent le premier signe détectable, parfois dès la naissance ou la petite enfance. Chez tout enfant ou adulte présentant une macrocéphalie inexpliquée associée à des lésions cutanées atypiques du visage ou à des antécédents familiaux de cancers multiples ou précoces, une consultation en génétique médicale pour évaluation du syndrome PTHS doit être envisagée.
Diagnostic Criteria (NCCN)
The clinical diagnosis of Cowden disease is based on the operational criteria of the National Comprehensive Cancer Network (NCCN), regularly revised according to new literature data:
- Pathognomonic criteria (each one is sufficient on its own to justify a PTEN genetic test): Lhermitte-Duclos disease in adults; multiple facial trichilemmomas (histologically confirmed); palmoplantar fibrokeratomas; mucosal papillomatosis (gingival cobblestoning or mucosal papillomatous lesions); macrocephaly (head circumference ≥ 97th percentile)
- Major criteria: breast cancer; non-medullary thyroid cancer (follicular or vesicular); macrocephaly; endometrial cancer; kidney cancer
- Minor criteria: other benign thyroid lesions (multinodular goiter, adenoma); mild intellectual disability (IQ ≤ 75); gastrointestinal hamartomas (including ganglioneuromas); multiple lipomas; fibromas; ovarian fibroma; colorectal cancer
- The PTEN genetic test is recommended by the NCCN in any individual presenting with: a pathognomonic criterion or; ≥ 2 major criteria (at least one of which is macrocephaly, breast cancer, or thyroid cancer) or; one major criterion + ≥ 3 minor criteria or; ≥ 4 minor criteria
- First-degree relatives of a person with a confirmed PTEN mutation should be systematically offered genetic testing, regardless of their clinical manifestations, to identify presymptomatic carriers who could benefit from early intensive surveillance.
Differential diagnosis
Several rare syndromes share clinical features with Cowden disease and must be distinguished:
| Syndrome | Gene involved | Distinctive elements |
|---|---|---|
| Bannayan-Riley-Ruvalcaba Syndrome (BRRS) | PTEN (same PTHS spectrum) | Macrocephaly, multiple lipomas, hemangiomas, melanotic pigmented spots of the male genitalia (penile lentigines); manifestations from childhood; no increased risk of cancer as a primary concern; part of the PTHS spectrum with Cowden disease |
| Peutz-Jeghers Syndrome | STK11 (LKB1) | Multiple gastrointestinal hamartomatous polyps (Peutz-Jeghers type); characteristic periorificial lentiginosis (brown spots around the mouth, nostrils, eyes, and on the fingers); high risk of cancers of the digestive tract, pancreas, breast, and genital organs; no facial trichilemmomas or Cowden-type mucosal lesions. |
| Juvenile polyposis | SMAD4, BMPR1A | Multiple colorectal hamartomatous polyps from childhood or adolescence; high risk of colorectal and gastric cancer; no skin manifestations nor risk of breast or thyroid cancer characteristic of Cowden; genetic analysis differentiates the two syndromes. |
| Lynch syndrome (HNPCC) | MLH1, MSH2, MSH6, PMS2 | High risk of colorectal, endometrial, ovarian, stomach, and urinary tract cancer; no hamartomas or characteristic skin manifestations; MSI and IHC testing on colorectal tumors as initial workup |
| Neurofibromatosis type 1 (NF1) | Neurofibromatosis type 1 | Multiple cutaneous neurofibromas, café-au-lait spots, iris hamartomas (Lisch nodules), optic pathway gliomas; may be confused with Cowden based on multiple cutaneous lesions but the clinical profile is very different; NF1 genetic analysis differentiates the two syndromes |
| Birt-Hogg-Dubé syndrome | FLCN foliculine | Multiple cutaneous fibrofolliculomas of the face and neck (mimicking Cowden's tricholemmomas), pulmonary cysts and spontaneous pneumothorax, renal cancer; FLCN genetic testing to differentiate from PTEN |
Oncology Monitoring Program
Intensified surveillance is the cornerstone of managing confirmed carriers of a PTEN mutation, aiming for early detection of associated cancers at a potentially curable stage. The recommendations below are based on the latest NCCN guidelines (2024):
| Target organ | Surveillance exam | Frequency and age of onset |
|---|---|---|
| Her | Clinical breast exam by a healthcare professional; annual mammogram + annual breast MRI (6-month interval between mammogram and MRI to cover the entire year) | Clinical examination every 6 to 12 months starting at age 25 or 5 to 10 years before the earliest family case; annual mammography + MRI from ages 30 to 35; biennial alternating surveillance (mammography in spring, MRI in fall) is recommended to maximize early detection given the frequent dense breast tissue in this syndrome |
| Thyroid | Annual thyroid ultrasound | From diagnosis or from 7 to 10 years old in children with a PTEN mutation; fine-needle aspiration of suspicious nodules according to ACR TI-RADS criteria |
| Endometrium | Annual transvaginal pelvic ultrasound and/or annual endometrial biopsy | Starting at 30 to 35 years old or 5 years before the earliest family case; consultation with gynecologic oncology to discuss surveillance vs. prophylactic surgery (hysterectomy) options in women who have completed their childbearing plans. |
| Colon and rectum | Colonoscopy | From age 35 (or 5 to 10 years before the earliest family case); every 5 years if the first screening is normal; every 1 to 3 years if polyps are detected |
| Rein | Abdominal MRI or renal ultrasound | Starting at age 40 according to some recommendations (NCCN); every 1 to 2 years; the recommendation varies depending on expert groups and individual family risk |
| Skin | Annual dermatological examination | From diagnosis; monitoring of characteristic skin lesions and screening for melanomas and skin carcinomas, for which the risk is slightly increased. |
| Lhermitte-Duclos disease | Brain MRI with gadolinium | If there are suggestive neurological symptoms (ataxia, diplopia, headaches of intracranial hypertension); no systematic brain MRI monitoring in the absence of symptoms according to current recommendations |
ℹ️
The option of prophylactic surgery (risk-reducing bilateral mastectomy, prophylactic hysterectomy) must be discussed individually with each patient with a PTEN mutation within the framework of a multidisciplinary oncogenetic consultation. These decisions depend on individual risk, family history, patient preferences, reproductive plans, and overall health status. They are not systematically recommended but represent a legitimate option that some very high-risk patients choose after full information.
Genetic counseling and family screening
The discovery of a PTEN mutation in a patient has significant implications for the entire family and warrants a structured genetic counseling approach:
- Any patient with a confirmed PTEN mutation should be referred to a medical geneticist or genetic counselor for a genetic counseling consultation to explain individual risks, mode of inheritance, implications for offspring, and surveillance or prevention options.
- Genetic testing should be offered to all first-degree relatives (parents, siblings, children) of a confirmed PTEN mutation carrier, regardless of their current clinical manifestations, in order to identify presymptomatic carriers who could benefit from an early surveillance program.
- For carrier couples wishing to conceive, preimplantation genetic diagnosis (PGD) in the context of in vitro fertilization is technically possible in Quebec for serious hereditary tumor syndromes with high penetrance, such as Cowden disease, allowing the selection of embryos not carrying the mutation before implantation.
- The announcement of a positive PTEN mutation result can have a significant psychological impact on the patient and their family (anxiety, parental guilt, existential questions about lifelong intensive surveillance); psychological support within a multidisciplinary cancer genetics team is recommended.
- In Quebec, genetic testing for hereditary tumor syndromes is available in university hospital centers (CHUs) through medical genetics and oncogenetics services, with reimbursement by the RAMQ for medically indicated tests.
Situations requiring immediate specialist assessment
Anyone presenting with a combination of atypical multiple facial skin lesions (translucent perinasal or peri-orbital papules, cobblestone appearance of the gums), macrocephaly, and a personal or family history of multiple or early cancers (breast cancer before age 50, thyroid cancer in a young adult, endometrial cancer, multiple cancers in the same person) should be referred for a consultation in medical genetics or oncogenetics for evaluation of PTEN Hamartoma Tumor Syndrome (PHTS) and PTEN genetic testing. Prompt management is particularly important as early intensified surveillance of at-risk organs can allow for early cancer detection and significantly improve prognosis.
For any questions about hereditary tumor syndromes, familial risk of cancer, or referrals to available cancer genetics resources in Quebec, Clinique Omicron offers medical consultations at its service points in Quebec and via telemedicine. To make an appointment, visit cliniqueomicron.ca.
Consult at Clinique Omicron
Clinique Omicron supports patients with lesions suggestive of hereditary tumor syndrome, a family history of multiple or early-onset cancers, or an abnormal PTEN genetic result requiring coordination of a surveillance program, at its service points in Quebec and via telemedicine. A physician or a nurse practitioner specializing in advanced practice (IPS) can coordinate the initial clinical assessment, prescribe appropriate screening tests, and refer to specialized teams in medical genetics, oncology, or gynecological oncology based on each patient's needs. To make an appointment, visit cliniqueomicron.ca.
The content of this page is for informational purposes only and does not substitute for the advice of a qualified healthcare professional. Cowden syndrome is a rare condition requiring specialized care in medical genetics and oncogenetics; consult a doctor for any suspected diagnosis or decisions regarding surveillance and prevention.
Omicron Clinic
Need to consult a doctor?
Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.
Insurance receipts. 7j/7. No family doctor required.